Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03421626 · ClinicalTrials.gov registry record
Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML)
A clinical trial, sponsored by Cepheid.
- Completed
- Registry status
- 266
- Enrollment target
NCT03421626: Completed study, sponsored by Cepheid.
NCT03421626 is a clinical trial that has completed, run by Cepheid. The registered enrollment target is 266 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03421626 has completed, sponsored by Cepheid.
- COMPLETED
- Registry status
- 266 participants
- Enrollment target
Study Summary
The objective of this study is to establish the performance of an assay that detects mRNA transcript levels in patients diagnosed with CML. The study is conducted at locations within the United States. Testing is performed on peripheral blood specimens provided by eligible enrolled patients. Results from this study will not be used for patient management decisions.
Primary Outcome
Comparison of Xpert to an on-market test for the quantitation of BCR-ABL
Interventions
- DEVICE Xpert BCR-ABL Ultra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 266 participants |
| Start Date | 2017-11-08 |
| Est. Completion | 2018-08-20 |
What the finished NCT03421626 record still lists
NCT03421626 is an observational study that tracks outcomes without assigning an intervention. The registered 266 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Xpert BCR-ABL Ultra is the first listed.
NCT03421626 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03421626 about?
NCT03421626 is a clinical study titled "Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML)". The objective of this study is to establish the performance of an assay that detects mRNA transcript levels in patients diagnosed with CML. The study is conducted at locations within the United States. Testing is performed on peripheral blood specimens provided by eligible enrolled patients. Results...
What is the current status of trial NCT03421626?
This trial is currently completed. The enrollment target is 266 participants. The study started on 2017-11-08. Estimated completion is 2018-08-20.
What interventions are being tested in trial NCT03421626?
The interventions under investigation include: Xpert BCR-ABL Ultra (DEVICE).
Who is sponsoring clinical trial NCT03421626?
This trial is sponsored by Cepheid, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05098652 · 266 participants · NA
Coaching Dementia Caregivers to Master Care-Resistant Behavior
- NCT06088277 · 266 participants · NA
Texting to Reduce Human Immunodeficiency Virus (HIV) Risk
- NCT06261814 · 266 participants · Phase 2
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
- NCT06312124 · 266 participants · NA
A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI